Details : Herceptin is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 29, 2016
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Details : Herceptin is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 25, 2012
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Details : Herceptin is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 04, 2012
Details : Herceptin is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 29, 2012
Details : Herceptin is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 25, 2011
Reset All
